FLSW - ETF AI Analysis
Top Page
Franklin FTSE Switzerland ETF (FLSW)
Rating:70Neutral
Price Target:―
Positive Factors
Low Expense Ratio
The fund charges a relatively low fee, which helps investors keep more of their returns over time.
Defensive Sector Tilt
Large weights in health care and consumer defensive companies can provide some stability during market downturns.
Recent Short-Term Momentum
The ETF has shown strong recent one-month performance, suggesting positive short-term price momentum.
Negative Factors
High Concentration in a Few Stocks
A small number of companies, such as Roche, Novartis, and Nestlé, make up a large share of the portfolio, increasing single-stock risk.
Several Top Holdings Are Lagging
Many of the largest positions, including Roche, Nestlé, UBS, and others, have shown weak year-to-date performance, which can drag on overall returns.
Limited Country Diversification
The ETF is heavily focused on Switzerland with only a modest allocation to the U.S., so it may be more affected by economic or market issues specific to Switzerland.
FLSW vs. SPDR S&P 500 ETF (SPY)
AUM81.76M
RegionEurope
Expense Ratio0.09%
Beta0.62
IssuerFranklin
Inception DateFeb 06, 2018
Dividend Yield2.03%
Asset ClassEquity
Index TrackedFTSE Switzerland RIC Capped Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,023
30 Day Avg. Volume10,860
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
46.43Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering48
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FLSW Summary
The Franklin FTSE Switzerland ETF (FLSW) is a fund that follows the FTSE Switzerland RIC Capped Index, giving you broad exposure to the Swiss stock market. It holds a mix of large, mid, and small companies across many sectors, including famous names like Nestlé and Novartis. This ETF can be useful if you want to diversify outside the U.S. and invest in stable, well-known Swiss businesses in areas like healthcare, finance, and consumer goods. A key risk is that its value can rise or fall with the Swiss stock market and currency movements.
How much will it cost me?The Franklin FTSE Switzerland ETF (FLSW) has an expense ratio of 0.09%, meaning you’ll pay $0.90 per year for every $1,000 invested. This is lower than average because it’s a passively managed fund that tracks an index, which typically involves lower costs compared to actively managed funds.
What would affect this ETF?The Franklin FTSE Switzerland ETF could benefit from Switzerland's stable economy and strong performance in sectors like healthcare and consumer defensive, which are less sensitive to economic downturns. However, challenges such as global economic slowdowns, regulatory changes in the pharmaceutical industry, or fluctuations in the financial sector could negatively impact its top holdings and overall performance.
FLSW Top 10 Holdings
FLSW leans heavily on Switzerland’s global champions, with health care and consumer staples setting the tone. Novartis has been a steady climber, quietly supporting returns, while Roche and Nestlé feel more like they’re catching their breath after earlier strength. The real spark lately comes from ABB, whose rising share price has been a key engine for the fund. Financial names like UBS and Zurich Insurance are more mixed, sometimes adding lift, sometimes acting as a brake. Overall, this is a concentrated bet on blue-chip Swiss stability rather than fast-moving global tech.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Roche Holding AG | 13.53% | $10.81M | $332.30B | 35.47% | 73 Outperform | |
| Novartis AG | 13.32% | $10.63M | CHF216.41B | 28.22% | 80 Outperform | |
| Nestlé SA | 11.94% | $9.54M | CHF202.28B | -6.56% | 71 Outperform | |
| ABB Ltd | 7.75% | $6.19M | CHF146.44B | 73.88% | 78 Outperform | |
| UBS Group AG | 5.23% | $4.18M | $141.97B | 48.10% | 73 Outperform | |
| Compagnie Financiere Richemont SA | 4.23% | $3.38M | CHF92.27B | -2.28% | 78 Outperform | |
| Zurich Insurance Group | 4.05% | $3.24M | CHF85.65B | 2.41% | 78 Outperform | |
| Holcim | 2.67% | $2.13M | CHF38.87B | -22.16% | 73 Outperform | |
| Swiss Re AG | 2.43% | $1.94M | CHF34.16B | -12.23% | 73 Outperform | |
| Lonza Group Ltd | 2.39% | $1.91M | CHF33.56B | -11.92% | 71 Outperform |
FLSW Technical Analysis
Positive
―
Price Trends
41.74
Positive
42.30
Positive
40.69
Positive
Market Momentum
0.29
Negative
58.42
Neutral
90.91
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FLSW, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 42.56, equal to the 50-day MA of 41.74, and equal to the 200-day MA of 40.69, indicating a bullish trend. The MACD of 0.29 indicates Negative momentum. The RSI at 58.42 is Neutral, neither overbought nor oversold. The STOCH value of 90.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FLSW.
FLSW Peer Comparison
Comparison Results
Performance Comparison
FLSW
Franklin FTSE Switzerland ETF
43.37
5.97
15.96%
EWL
iShares MSCI Switzerland ETF
―
―
―
FGM
First Trust Germany AlphaDEX Fund
―
―
―
DBEZ
Xtrackers MSCI Eurozone Hedged Equity ETF
―
―
―
FLEU
Franklin FTSE Eurozone ETF
―
―
―
FSZ
First Trust Switzerland AlphaDEX Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents